AMRN — AMARIN CORP PLC\UK
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 897448 ·
Ireland
Last close
$14.88
Market Cap
$312.02M
52W High
$17.25
52W Low
$12.96
ADV30
95,376
Next earnings
2026-07-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 45,132,000 | 17,769,000 | -8,011,000 | -10,512,000 | 645,764,000 | 131,063,000 | 196,351,000 |
| Dec 2025 | 49,219,000 | 23,169,000 | -2,261,000 | -1,224,000 | 670,775,000 | 134,660,000 | 211,494,000 |
| Sep 2025 | 49,670,000 | 22,208,000 | -1,697,000 | -7,738,000 | 659,814,000 | 122,802,000 | 200,920,000 |
| Jun 2025 | 72,741,000 | 50,362,000 | 6,774,000 | -14,139,000 | 670,126,000 | 147,877,000 | 205,202,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$25,575,000
Investing CF
$-11,533,000
Financing CF
$-2,602,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.60
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,717,856,000
Inventory
$183,585,000
Receivables
$108,051,000
ST Investments
$176,759,000
EBIT TTM
$-27,295,000
Pretax Income TTM
$-31,140,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$216,760,992
EBITDA
$-2,261,000
Free Cash Flow
$2,224,500
Enterprise Value
$16,931,928
Total Cash
$307,822,016
Total Debt
$7,701,000
Shares Out
20,969,109
Trailing EPS
$-1.60
Book Value
$21.42
ROE
-7.3%
ROA
-0.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 213,646,000 | -13,941,000 | -38,798,000 | 670,775,000 | 211,494,000 | — | 6,728,000 |
| Dec 2024 | 228,614,000 | -91,797,000 | -82,183,000 | 685,349,000 | 199,173,000 | — | -31,020,000 |
| Dec 2023 | 306,911,000 | -56,616,000 | -59,112,000 | 831,684,000 | 279,587,000 | — | 6,880,000 |
| Dec 2022 | 369,193,000 | -92,343,000 | -105,803,000 | 886,179,000 | 290,846,000 | — | -180,092,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.98
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $14.00 · spot: $14.88 · call volume: 51 · put volume: 127
Expected Move to 2026-07-17:
±$1.29
(8.67%) —
implied range
$13.59 –
$16.17
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | $311.93M | $4.80 | — |
| ORGO | Organogenesis Holdings Inc. | $308.82M | $2.40 | — |
| CYDY | CytoDyn Inc. | $320.52M | $0.23 | — |
| IFRX | InflaRx N.V. | $301.95M | $2.05 | — |
| IRD | Opus Genetics, Inc. | $323.66M | $3.92 | — |
News headlines (Yahoo Finance, 1h cache)
Immunome Stock Up 32% in a Month: Here's What You Should Know
2026-07-10 14:40 · Yahoo
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data
2026-07-10 14:18 · Yahoo
Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now
2026-07-10 13:55 · Yahoo
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know
2026-07-09 18:26 · Yahoo
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
2026-07-09 14:52 · Yahoo
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
2026-07-08 14:32 · Yahoo
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia
2026-07-07 12:58 · Yahoo
Reasons Why Investors Should Consider Betting on Neurocrine Stock
2026-07-06 14:45 · Yahoo
UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal
2026-07-03 12:55 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
2026-07-02 15:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.